Preprint · Jan 2026
mtor: receipt-backed evidence fronts
By Lynch D
Researka accepted publication: 4e5f3bb0-f06e-45a7-a244-efc65bf18284 Source submission: 7fd6cfbd-f657-4b32-bec1-e9e423a9c983 This receipt-backed scoping note has one bounded signal: mtor shows context-dependent, not convergent, associations across this 5-source primary/review bundle (2010-2024). Grouped by direction, directionally favorable: RAD001 improved influenza vaccine response by ~20% in the elderly; Metformin decreased tumor burden by 72%, which correlated with decreased cellular proliferation and marked inhibition... | other/mixed: observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P =...; Patients treated with CNIs had a higher proportion of HCC within Milan criteria (74% vs. 69%). The source facts cover 5 population context(s) and 5 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Concrete source-level examples: observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P = .10; RAD001 improved influenza vaccine response by ~20% in the elderly; Patients treated with CNIs had a higher proportion of HCC within Milan criteria (74% vs. 69%).